Cost-effectiveness of Oral Protease Inhibitors Co-administration versus Pegylated Interferon-Α2b and Ribavirin Only for the Patients with Hepatitis C Genotype 1 in Kazakhstan Health Care Settings
Iran J Public Health, Vol. 47, No.12, Dec 2018, pp.1845-1853
Авторы:
A. ALMADIYEVA Dept. of Public Health, Astana Medical University/ S. IBRAYEV Dept. of Public Health, Astana Medical University/ A. TURGAMBAYEVA Dept. of Public Health, Astana Medical University/ A. KOSTYUK National Center for Medicines, Medical Devices and Medical Equipment Expertise./ Z. KHISMETOVA Dept. of Public Health, Semey State Medical University/ Zh. AKHMETOVA Dept. of Public Health, Astana Medical University